Telbolife Trio 6.25 Tablet combines Telmisartan 40mg, Cilnidipine 10mg, and Chlorthalidone 6.25mg, a potent triple-action antihypertensive formulation designed for optimal blood pressure and cardiovascular management. This combination addresses high blood pressure, vascular resistance, and fluid retention simultaneously.
Telmisartan, an angiotensin receptor blocker, helps relax blood vessels and lower blood pressure. Cilnidipine, a calcium channel blocker, reduces peripheral resistance, while Chlorthalidone, a thiazide-like diuretic, helps control fluid balance and reduces hypertension-related complications. Together, they provide comprehensive cardiovascular protection.
This triple-combination tablet is widely prescribed in patients with moderate-to-severe hypertension, resistant hypertension, and those at high cardiovascular risk. Its balanced efficacy and tolerability make it a preferred therapy among cardiologists and general physicians.
Adding Telbolife Trio 6.25 Tablet to your cardiology and antihypertensive portfolio strengthens your product line with a clinically effective, high-demand combination. It offers strong opportunities for hospital supply, retail pharmacy distribution, institutional tenders, export channels, and third-party manufacturing, ensuring consistent market demand and profitability.